ClinicalTrials.gg

Program

mRNA-1010 influenza vaccine

Also written as “mRNA-1010”, “mRNA-1010.4” and “mRNA-1010.6”.

Its studies are mostly in Influenza, Human · Coronavirus Infections, led by Moderna.

Furthest: phase 4, since Oct 13, 202612 company-led studies, 2 open or runningNext primary completion: Dec 7, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna122 open or runningphase 4since Oct 13, 2026Jun 30, 2021Dec 7, 2026phase 4 · NCT07884175

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2021First study: phase 2 study in Influenza, HumanFirst studyNCT04956575 · 885 enrolled · United States
  2. May 13, 2022Phase 2 study in Influenza, HumanNCT05375838 · 550 enrolled · United States
  3. May 25, 2022Phase 1 study in Coronavirus InfectionsNCT05397223 · 308 enrolled · United States
  4. Jun 8, 2022Phase 3 study in Seasonal InfluenzaNCT05415462 · 6,102 enrolled · Argentina, Australia, Colombia and more
  5. Sep 30, 2022Phase 3 study in Influenza, HumanNCT05566639 · 22,502 enrolled · United States, Bulgaria, Canada and more
  6. Oct 14, 2022Phase 1 study in Influenza, HumanNCT05585632 · 392 enrolled · United States, Australia, United Kingdom
  7. Oct 31, 2022Phase 2 study in Influenza, HumanNCT05606965 · 172 enrolled · United States
  8. Apr 13, 2023Phase 3 study in Virus DiseasesNCT05827978 · 8,411 enrolled · United States
  9. May 11, 2023Phase 2 study in Influenza, HumanNCT05868382 · 270 enrolled · United States
  10. Sep 15, 2024Phase 3 study in Influenza, HumanNCT06602024 · 40,805 enrolled · United States, Belgium, Bulgaria and more
  11. Oct 6, 2026Phase 1 study in Influenza, HumanNCT07870330 · 96 planned · United States
  12. Oct 13, 2026Phase 4 study in Influenza, HumanNCT07884175 · 200 planned · United States

Ahead

  1. Dec 7, 2026Primary completion: phase 4 study in Influenza, HumanNCT07884175
  2. Dec 7, 2027Primary completion: phase 1 study in Influenza, HumanNCT07870330

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07884175Influenza, Human · United States4RecruitingDec 7, 2026200
NCT07870330Influenza, Human · United States1RecruitingDec 7, 202796
NCT06602024Influenza, Human · United States, Belgium, Bulgaria and more3CompletedAug 21, 202540,805
NCT05868382Influenza, Human · United States2CompletedDec 19, 2023270
NCT05827978Virus Diseases · United States3CompletedJun 24, 20248,411
NCT05606965Influenza, Human · United States2CompletedNov 13, 2025172
NCT05585632Influenza, Human · United States, Australia, United Kingdom1CompletedFeb 28, 2024392
NCT05566639Influenza, Human · United States, Bulgaria, Canada and more3CompletedJan 5, 202422,502
NCT05415462Seasonal Influenza · Argentina, Australia, Colombia and more3CompletedSep 4, 20236,102
NCT05397223Coronavirus Infections · United States1CompletedFeb 27, 2026308
NCT05375838Influenza, Human · United States2CompletedDec 29, 2022550
NCT04956575Influenza, Human · United States2CompletedSep 27, 2022885

How it is read

Names in the registry

  • “mRNA-1010”, 12 entries
  • “mRNA-1010.4”, 1 entry
  • “mRNA-1010.6”, 1 entry

Codes read as this program: MRNA1010.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.